Related references
Note: Only part of the references are listed.Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
George C. Prendergast et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.
Mario R. Mautino et al.
CANCER RESEARCH (2014)
Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
Trine Zeeberg Iversen et al.
CLINICAL CANCER RESEARCH (2014)
Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!
Maria G. Castro et al.
CLINICAL CANCER RESEARCH (2014)
Regulatory T cells in cancer immunotherapy
Hiroyoshi Nishikawa et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205
Madhav V. Dhodapkar et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Minghui Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression
Jing-Yi Chen et al.
BREAST CANCER RESEARCH (2014)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2013)
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Michael Platten et al.
CANCER RESEARCH (2012)
Indoleamine 2,3-dioxygenase, Tregs and Cancer
D. H. Munn
CURRENT MEDICINAL CHEMISTRY (2012)
Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
Theodore S. Johnson et al.
IMMUNOLOGICAL INVESTIGATIONS (2012)
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR A novel IDO effector pathway targeted by D-1-methyl-tryptophan
Richard Metz et al.
ONCOIMMUNOLOGY (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
Regulation of Expression and Function of IDO in Human Dendritic Cells
A. Heitger
CURRENT MEDICINAL CHEMISTRY (2011)
Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
Eduard Dolusic et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells
Huai-Chia Chuang et al.
NATURE IMMUNOLOGY (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive Mice
Madhav D. Sharma et al.
IMMUNITY (2010)
Dendritic Cells, Indoleamine 2,3 Dioxygenase and Acquired Immune Privilege
Lei Huang et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2010)
Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
Holly K. Koblish et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
Nam Trung Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Antonio Curti et al.
BLOOD (2009)
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells
David J. Chung et al.
BLOOD (2009)
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes
Madhav D. Sharma et al.
BLOOD (2009)
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
Stefan Loeb et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-γ
Selim Corm et al.
LEUKEMIA RESEARCH (2009)
Neuropsychiatric disorders related to interferon and interleukins treatment
Aye Mu Myint et al.
METABOLIC BRAIN DISEASE (2009)
Halofuginone Inhibits TH17 Cell Differentiation by Activating the Amino Acid Starvation Response
Mark S. Sundrud et al.
SCIENCE (2009)
Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
S. Rutella et al.
Endocrine Metabolic & Immune Disorders-Drug Targets (2009)
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Stefan Loeb et al.
NATURE REVIEWS CANCER (2009)
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality
Lisa K. Jasperson et al.
BLOOD (2008)
Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival
Kazuhiko Ino et al.
CLINICAL CANCER RESEARCH (2008)
Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges
Jianchao Quan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism
Olivier Manches et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Spontaneous renal allograft acceptance associated with Regulatory dendritic cells and IDO
Charles H. Cook et al.
JOURNAL OF IMMUNOLOGY (2008)
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation
Wei Chen et al.
JOURNAL OF IMMUNOLOGY (2008)
Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors (vol 51, pg 1712, 2008)
Sanjeev Kumar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase
T. Banerjee et al.
ONCOGENE (2008)
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Stefan Lob et al.
BLOOD (2008)
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
Madhav D. Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan
Richard Metz et al.
CANCER RESEARCH (2007)
Immune signatures off murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy
Rebecca E. Sadun et al.
CLINICAL CANCER RESEARCH (2007)
Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice
Helen J. Ball et al.
GENE (2007)
Transcriptional regulation of indoleamine 2,3-dioxygenase (IDO) by tryptophan and its analogue
Takeaki Okamoto et al.
CYTOTECHNOLOGY (2007)
Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study
M. Pertovaara et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase
A. Curti et al.
LEUKEMIA (2007)
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
De-Yan Hou et al.
CANCER RESEARCH (2007)
CD40Ig treatment results in allograft acceptance mediated by CD8(+)CD45RC(low) T cells, IFN-gamma, and indoleamine 2,3-dioxygenase
Carole Guillonneau et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Indoleamine 2,3-dioxygenase in hematopoietic stem cell transplantation
U. Hainz et al.
CURRENT DRUG METABOLISM (2007)
Chronic immune activation underlies morbid obesity: Is IDO a key player?
G. Brandacher et al.
CURRENT DRUG METABOLISM (2007)
Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients
Georg Weinlich et al.
DERMATOLOGY (2007)
Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua
Harry C. Brastianos et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
K. Ino et al.
BRITISH JOURNAL OF CANCER (2006)
Tryptophan catabolism generates autoimmune-preventive regulatory T cells
Francesca Fallarino et al.
TRANSPLANT IMMUNOLOGY (2006)
Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: Implications for the control of alloresponses
SC Beutelspacher et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
G Brandacher et al.
CLINICAL CANCER RESEARCH (2006)
Structure-activity study of Brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors
P Gaspari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite
M Platten et al.
SCIENCE (2005)
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
V Lennerz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation
D Braun et al.
BLOOD (2005)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
Tryptophan degradation in patients with gynecological cancer correlates with immune activation
K Schroecksnadel et al.
CANCER LETTERS (2005)
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
AM Ercolini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer
S Astigiano et al.
NEOPLASIA (2005)
Dendritic cells have the option to express IDO-mediated suppression or not
DH Munn et al.
BLOOD (2005)
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
DH Munn et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Tryptophan and the immune response
JR Moffett et al.
IMMUNOLOGY AND CELL BIOLOGY (2003)
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase
DH Munn et al.
SCIENCE (2002)
Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer
A Huang et al.
BRITISH JOURNAL OF CANCER (2002)
Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses
AL Mellor et al.
JOURNAL OF IMMUNOLOGY (2002)
Regulated translation initiation controls stress-induced gene expression in mammalian cells
HP Harding et al.
MOLECULAR CELL (2000)
Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation
P Hwu et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
